Results 191 to 200 of about 49,828 (259)

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects: the example of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease. [PDF]

Am J Epidemiol
Wang T, Wang J, Song Z, Miller E, Pate V, Her Q, Yang J, Charlier SHR, Egger P, Barnes EL, Buse JB, Becker C, Sandler RS, Meier C, Jick S, Stürmer T.   +15 more
europepmc   +1 more source

Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike, Yoko Irie, Yuji Doi, Ryosuke Kemmotsu, Moe Kusushita, Yasuna Sakai, Tomonori Okita, Hiroyuki Sho, Ryoko Inui, Yukiko Tabuchi, Tetsuyuki Yasuda   +10 more
wiley   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis. [PDF]

Int J Cardiol Heart Vasc
Holt MF, Michelsen AE, Flø A, Russell K, Beitnes JO, Kløve SF, Hodt A, Gullestad L, Aukrust P, Gude E, Broch K, Ueland T.   +11 more
europepmc   +1 more source

Adaptive islet biology and comprehensive incretin physiology: Emerging perspectives from Asia and Europe

Journal of Diabetes Investigation, EarlyView.
Adaptive islet biology and incretin physiology provide a framework linking diverse diabetes phenotypes, with advances in β‐cell stress adaptation, intra‐islet communication, receptor‐resolved biology, and β‐cell mass imaging. By integrating clinical perspectives from Asia and Europe with multiscale islet‐cell biology, these insights may support ...
Takaaki Murakami, Daniela Nasteska, David J. Hodson, Yuji Yamazaki, Daisuke Yabe, Yutaka Seino   +5 more
wiley   +1 more source

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

Waist‐to‐height ratio and renal dysfunction as independent correlates of low handgrip strength in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen, Chen‐Kai Chou, Shao‐Wen Weng, Jung‐Fu Chen, Feng‐Chih Shen   +4 more
wiley   +1 more source

In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]

J Endocr Soc
Galsgaard KD, Abba V, Kuhre RE, Holst JJ, Hartmann B.   +4 more
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Phenotype-Specific Mortality Outcomes with Dipeptidyl Peptidase-4 Inhibitors in Heart Failure and Diabetes: Real-World Evidence from a Retrospective Single-Center Cohort Study. [PDF]

J Clin Med
Alfehaid L, Alamer A, Alhantush A, Yami MSA.   +3 more
europepmc   +1 more source